newsfilter
← Latest News
Business Wire·

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Acquisition strengthens Revvity’s position in human-relevant life sciences tools for next-generation GLP-1 and GPCR-targeting therapies for metabolic drug discovery Combines HCD’s human pancreatic beta cell models